Market Pulse Archives

June 20, 2016, 7:44 a.m. EDT

Syros Pharmaceuticals sets IPO price expectations

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Syros Pharmaceuticals Inc. (SYRS)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore


Syros Pharmaceuticals /zigman2/quotes/201168308/composite SYRS -0.44% said in a filing Monday that it expects its initial public offering of stock to price between $14 and $16 a share. The biopharmaceutical company, which has developed a gene-control platform, said it will offer 4 million common shares for sale in its IPO, to raise up to $64 million, before fees. Including options granted to the underwriters to purchase additional shares, the company could raise up to $73.6 million, before fees. The company expects the proceeds from the IPO to be sufficient to enable it to reach clinical activity data readouts its SY-1425 product candidate for treating acute myelogenous leukemia and myelodysplastic syndrome, and its SY-1365 candidate for treating acute leukemias. The company plans to list the stock on Nasdaq under the symbol "SYRS."

US : U.S.: Nasdaq
$ 4.48
-0.02 -0.44%
Volume: 37,911
Jan. 30, 2023 10:39a
P/E Ratio
Dividend Yield
Market Cap
$91.02 million
Rev. per Employee

Get news alerts on Syros Pharmaceuticals Inc. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.